Participants in this study will have one visit to the Emory University Hospital Clinical Research Unit. Participants will consume, over 5 minutes, a single standardized fat challenge (100 grams), using a commercially available liquid high-energy long chain triglyceride fat emulsion (Calogen), which provides 50 grams of long chain triglycerides per 100 mL. Participants will have 20 mL blood withdrawn at six successive time points over an 8-hour period, where the first time point after fasting (baseline) is followed by 5 time-points after fat consumption. Blood will be analyzed for a wide panel of blood lipids.
Cardiovascular disease (CVD) is the leading killer of Americans, accounting more than 800,000 deaths each year. A vital step in reducing the number of heart disease-related deaths in the U.S. is to identify those at probable risk. The Clinical Chemistry Branch (CCB) in the Division of Laboratory Sciences (DLS) at the Centers for Disease Control and Prevention (CDC) has developed advanced analytical methods for assessing the risk for lipid metabolism related diseases, including CVD. CCB of the CDC has developed a comprehensive analytical method to measure levels of protein and lipid constituents of lipoprotein size/density classes (e.g. high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) in blood. CCB plans to eventually apply this method in future investigations of cohorts with different CVD states. The measurement of this wide array of CVD-linked biomarkers has the potential to improve the assessment of CVD risk over current clinical methods based on lipoprotein classes. However, limited information is available about how the advanced tests developed by CCB are affected by blood collection conditions, such as fasting/non-fasting state of the subjects. The purpose of this study is to determine the relative significance of these pre-analytical variables and determine optimal conditions for future cohort studies. This study will recruit up to 32 healthy individuals, with and without obesity, to participate. The study involves one visit to the Emory University Hospital Clinical Research Unit where participants will consume, over 5 minutes, a single standardized fat challenge (100 grams), using a commercially available liquid high-energy long chain triglyceride fat emulsion (Calogen; http://www.nutricia.ie/calogen#), which provides 50 grams of long chain triglycerides per 100 mL. Participants will have 20 mL blood withdrawn at six successive time points over an 8-hour period, where the first time point after fasting is followed by 5 time-points after fat (Calogen) consumption. Blood will be analyzed at the CCB for a wide panel of blood lipids and potential biomarkers for CVD. Specific expected outcomes of the study include the following: 1) Determination of typical intra-individual differences between fasting and post-prandial states; and 2) Changes in the levels of the various analytes after fat consumption will be indicative of inter-individual differences in the rate of triglyceride depletion, and the rate of accumulation/depletion of HDL or LDL of different particle size range and composition. The results will allow the assessment of significant differences in lipid metabolism between individuals with a normal BMI (20 to 25 kg/m\^2) versus those with a BMI in the obese range (30-35 kg/m\^2).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
32
After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
Emory University Hospital
Atlanta, Georgia, United States
Change in high-density lipoprotein (HDL) Size
HDL concentration size profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. HDL is considered to be anti-atherogenic because of its ability deplete excess cholesterol accumulating necrotic cores and repair arterial lesions.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in low-density lipoprotein (LDL) Size
LDL concentration size profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. LDL is considered to be atherogenic because it is likely to be trapped inside the intima of blood vessels and arteries and initiate inflammatory response, foam-cell formation, and smooth muscle cell proliferation, leading to development necrotic cores, lesions, plaques and their eventual rupture. Elevated LDL has been thought to contribute to atherosclerotic events, however, research has also observed coronary events occurring in individuals with LDL levels in the acceptable range.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Total Cholesterol
Total cholesterol profiles for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Elevated total cholesterol has been thought to contribute to atherosclerotic events, however, research has also observed coronary events occurring in individuals with total cholesterol levels in the acceptable range.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Free Cholesterol
Free cholesterol concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Free cholesterol is unesterified cholesterol that is circulating in the blood stream.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Cholesterol Ester
Cholesterol ester concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Lipoproteins contain cholesterol ester, and cholesterol ester is associated with atherosclerosis.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Triglycerides
Triglyceride concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI. Triglycerides peak in serum 2 to 4 hours after a meal and return to a pre-meal state in 6 to 8 hours.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Phosphatidylinositol
Phosphatidylinositol concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Phosphatidylethanolamine
Phosphatidylethanolamine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Phosphatidylcholine
Phosphatidylcholine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Sphingomyelin
Sphingomyelin concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Lysophosphatidylcholine
Lysophosphatidylcholine concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein AI
Apolipoprotein AI concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein AII
Apolipoprotein AII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein AIV
Apolipoprotein AIV concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein B
Apolipoprotein B concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein CI
Apolipoprotein CI concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein CII
Apolipoprotein CII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein CIII
Apolipoprotein CIII concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Apolipoprotein E
Apolipoprotein E concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Lecithin-Cholesterol Acyltransferase
Lecithin-cholesterol acyltransferase concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Cholesterol Ester Transfer Protein
Cholesterol ester transfer protein concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Lipoprotein (a)
Lipoprotein (a) concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Phospholipid Transfer Protein
Phospholipid transfer protein concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Serum Paraoxonase/arylesterase 1
Serum paraoxonase/arylesterase 1 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Serum Amyloid A1
Serum amyloid A1 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6
Change in Serum Amyloid A4
Serum amyloid A4 concentration for each time-point will be compared between participants with normal BMI and participants with obese range BMI.
Time frame: Hours 0, 0.5, 1, 2, 4, and 6